Forty years of the Danaher Business System, on one filterable page.
Steven and Mitchell Rales bought a small industrial holding company called DMG Corporation in 1984, renamed it Danaher after a Montana river where they had fished as boys, and proceeded to execute what has become the archetypal record of disciplined serial acquisition compounding — roughly 400 acquisitions over four decades, integrated through the Danaher Business System (DBS), the operating rhythm that practitioners describe as "Toyota Production System meets M&A discipline." Three transformative spinoffs — Fortive in 2016, Envista in 2019, and Veralto in 2023 — each carried out a self-contained platform that has itself become a serial acquirer running DBS. This page catalogs the material transactions on the record: whole-company acquisitions, corporate carve-outs, public-company mergers, and the three spinoff exit events. It is intentionally a living reference: as new deals close, the row is added, the roll-ups reflow, and the sitemap timestamp bumps. Nothing here is investment advice. Everything here is a fact-checkable practitioner reference for a very specific question — what does forty years of DBS-driven capital deployment actually look like in list form?
Nine columns. Year of announcement or close. Target name. Danaher operating platform at time of acquisition (Life Sciences, Diagnostics, Biotechnology, Water Quality, Product Identification, Industrial Technology, Dental, Motion, Environmental, or Corporate). Approximate consideration in USD (illustrative where deal size was not publicly disclosed — marked "n/d" for not-disclosed or "approx"). Deal structure. Counterparty type. The DBS-platform integration flag — the defining Danaher acquisition pattern: was the target folded into the Danaher Business System operating rhythm, becoming a permanent piece of a platform, or was it a portfolio holding that was later divested or spun off? Distinctive notes. Current status — held, divested, spun off to Fortive/Envista/Veralto, or merged into another Danaher subsidiary.
Sort and filter. Click any column header to sort. Use the decade, platform, structure, counterparty, and DBS-integration filters to isolate a slice. The search box matches target names and notes.
What counts as an acquisition. This record focuses on material transactions — deals over roughly $100 million, or strategically significant platform-defining bolt-ons. Danaher has executed something on the order of 400 acquisitions since 1984; enumerating every small tuck-in would obscure the pattern. What appears here is the list a practitioner needs to see to understand how Danaher built its earnings power — from an industrial roll-up in the 1990s, through the diversification and healthcare pivot of the 2000s, into the life-sciences and biotech transformation of the 2010s and 2020s. The three spinoff events (Fortive 2016, Envista 2019, Veralto 2023) are included as structural entries with "Spinoff" as the deal structure.
DBS-platform integration marker. A YES flag means the target was folded into the Danaher Business System operating rhythm and became a permanent part of a Danaher (or successor Fortive/Envista/Veralto) platform. A NO flag means the transaction was a financing, a minority stake, a distressed rescue, or an acquisition that Danaher later divested rather than integrated. The overwhelming majority of Danaher acquisitions carry the DBS integration marker — that is the whole point of the model, and it is why Danaher's compounding record is best understood as an operating compounder rather than a portfolio compounder.
Every material Danaher acquisition since Steven and Mitchell Rales formed the company in 1984, on one page — plus the three transformative spinoffs (Fortive 2016, Envista 2019, Veralto 2023) that themselves inherited and extended the Danaher Business System. Sortable by year, platform, deal size, structure, and counterparty type — with the DBS-platform integration pattern flagged across four decades. Search by target name (Beckman Coulter, Pall, Cepheid, Cytiva, Radiometer, Leica Microsystems, Aldevron, Abcam, Videojet, Fluke, Tektronix, Trojan, Hach, Nobel Biocare, KaVo, Ormco), by platform (Life Sciences, Diagnostics, Biotechnology, Water Quality, Product Identification, Industrial Technology, Dental), or by structure (whole-company, carve-out, public-company merger, spinoff). Every row is a fact-checkable reference. This is a living dataset — updated whenever Danaher, Fortive, Envista, or Veralto closes a new material deal.
| Year | Target | Platform | Consideration | Structure | Counterparty | DBS? | Notes | Status |
|---|
Roll-ups reflect the material acquisitions cataloged in the table above. Where consideration is undisclosed, the deal is included in count-based roll-ups but excluded from dollar-based totals. Dollar figures are illustrative aggregates — the point is directional, not audit-grade.
Whole-company and carve-out purchases only; spinoffs and minority stakes excluded from the dollar totals. The 2010s dollar figure is dominated by Pall ($13.8B), Beckman Coulter ($6.8B), and Cepheid ($4B). The 2020s are dominated by Cytiva ($21.4B) and Aldevron ($9.6B). Bar length is proportional within this table only.
Whole-company acquisitions dominate the deal count. Carve-outs — Danaher buying a business line out of a larger parent, then rebuilding it under DBS — are the second-most common structure, and are the Cytiva-Aldevron-Videojet signature move.
Platform is captured at time of the transaction — a Water Quality target from 1998 stayed classified as Water Quality even after it was later spun off with Veralto in 2023. Life Sciences, Diagnostics, and Biotechnology together dominate the modern (post-2015) count.
The signature Danaher acquisition pattern. Nearly every whole-company and carve-out acquisition Danaher has executed has been folded into DBS operating rhythm — this is not a portfolio compounder, it is an operating compounder, and DBS is the compounding engine.
An acquisition record is a lagging indicator. The leading indicator for Danaher is twofold: (1) the three independent spinoff platforms — Fortive, Envista, and Veralto — that each carry DBS forward as autonomous serial acquirers, and (2) the active bolt-on pipeline inside Danaher's Life Sciences, Diagnostics, and Biotechnology platforms, which continues to consolidate the fragmented tools, reagents, and instrumentation vendors that support the biopharma industry.
Spun off July 2016. The industrial technology and instrumentation platform — Fluke, Tektronix, Gilbarco Veeder-Root, Matco Tools, Kollmorgen, and later add-ons. Fortive itself has since spun off Vontier (2020) and continues serial acquisitions in industrial software and specialty test-and-measurement.
Spun off September 2019. The dental platform — KaVo Kerr, Nobel Biocare, Ormco, Metrex, DEXIS, and companion consumable and orthodontic assets. Envista runs a lighter-touch DBS on a narrower vertical.
Spun off October 2023. Water Quality (Hach, Trojan Technologies, ChemTreat, McCrometer) plus Product Identification (Videojet, X-Rite, Pantone, Esko, Linx). The most recent carve-out; Veralto has continued small-to-medium bolt-ons since separation.
Post-Cytiva and post-Aldevron, Danaher continues to consolidate biopharma-adjacent tools and reagents. Abcam (2023, $5.7B) added antibody and research-reagents scale. Expect continued tuck-ins across bioprocessing, gene therapy manufacturing, and molecular biology reagents — the durable secular growth areas Danaher has explicitly targeted.
Danaher belongs to the small handful of records that define the modern compounding era. These are the companion practitioner references and case memos already published on the Institute site.
Educational reference. Not investment advice. Not a solicitation. Not affiliated with Danaher Corporation, Fortive Corporation, Envista Holdings, Veralto Corporation, or any of their subsidiaries. The Baratelli Institute publishes under the Lowe v. SEC publisher exception; neutral positioning maintained throughout. Deal figures cited in this catalog are sourced primarily to Danaher (and successor Fortive, Envista, Veralto) annual reports and 10-K filings, S&P and Moody's rating actions, contemporaneous press coverage (Wall Street Journal, Financial Times, Bloomberg, Reuters, industry press including STAT News and BioProcess International), and standard reference works on Danaher's history including practitioner writeups of the Danaher Business System. Dollar amounts are approximate. Where a specific transaction date or dollar figure is not publicly disclosed — a common condition for small bolt-ons and non-U.S. private-target acquisitions — the row is flagged with "approx" or "n/d" (not disclosed) in the notes column rather than fabricating precision. The full record of 400+ Danaher acquisitions cannot be enumerated publicly; this catalog focuses on the material transactions (roughly $100M+ or strategically platform-defining) that shape the compounding record.
“We do not buy companies. We buy platforms — and then we operate them.”